Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIELLE M BRANDER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1144497553
CMS profile
233269
Location
DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$10,733.28

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Verastem, Inc. $8,902.42 16
Genentech, Inc. $1,300.00 1
PFIZER INC. $335.99 2
Genentech USA, Inc. $116.86 1
AbbVie, Inc. $78.01 1

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIELLE M BRANDER

NPI 1144497553 · CMS profile ID 233269

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DURHAM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIELLE M BRANDER, NPI 1144497553, CMS profile ID 233269. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DANIELLE M BRANDER, NPI 1144497553, CMS profile ID 233269. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DANIELLE M BRANDER, NPI 1144497553, CMS profile ID 233269, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144497553?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $10,733.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $78.0112/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648087005 CMS
Genentech USA, Inc. $116.8612/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681141929 CMS
PFIZER INC. $128.3412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673853115 CMS
PFIZER INC. $207.6512/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673853117 CMS
Verastem, Inc. $2,175.0010/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791377 CMS
Verastem, Inc. $44.0008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791357 CMS
Verastem, Inc. $47.7708/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791361 CMS
Verastem, Inc. $5,075.0007/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791317 CMS
Verastem, Inc. $75.4106/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791327 CMS
Verastem, Inc. $252.0006/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791331 CMS
Verastem, Inc. $75.1006/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791334 CMS
Verastem, Inc. $113.8506/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791337 CMS
Verastem, Inc. $30.0006/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791341 CMS
Verastem, Inc. $25.0006/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791345 CMS
Verastem, Inc. $47.2606/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791349 CMS
Verastem, Inc. $78.5406/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791353 CMS
Verastem, Inc. $77.3706/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791371 CMS
Verastem, Inc. $428.6006/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791321 CMS
Verastem, Inc. $282.1106/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791323 CMS
Verastem, Inc. $75.4106/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699791367 CMS
Genentech, Inc. $1,300.0003/04/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681168447 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,733.28 21
PY2020 $1,676.00 2
PY2024 $6,544.07 5
PY2025 $2,537.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,449,633.69 67
PY2024 Principal investigator $2,178,707.78 124
PY2023 Principal investigator $670,662.81 39
PY2022 Principal investigator $319,423.50 21
PY2021 Recipient $15.58 1
PY2021 Principal investigator $1,263,815.47 56
PY2020 Principal investigator $2,651,847.30 70
PY2019 Principal investigator $68,831.32 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $114,504.94 12/31/2021 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1,2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies No dispute reported 06/30/2026 848740505
Principal investigator 1 TG Therapeutics, Inc. $5,040.00 12/16/2021 Non-covered Recipient Entity
Duke Medical Center
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 No dispute reported 06/30/2026 850452259
Principal investigator 1 BeiGene, Ltd. $6,416.00 12/15/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872667
Principal investigator 1 BeiGene, Ltd. $3,209.00 12/15/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872669
Principal investigator 1 BeiGene, Ltd. $2,830.00 12/15/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872671
Principal investigator 1 BeiGene, Ltd. $260.00 12/15/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872675
Principal investigator 1 BeiGene, Ltd. $2,481.00 12/15/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872677
Principal investigator 1 BeiGene, Ltd. $6,199.13 12/13/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872665
Principal investigator 1 BeiGene, Ltd. $1,826.09 11/19/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872673
Recipient TG Therapeutics, Inc. $15.58 11/18/2021 Covered Recipient Physician UTXTGR205 No dispute reported 06/30/2026 850450807
Principal investigator 1 TG Therapeutics, Inc. $4,720.00 11/08/2021 Non-covered Recipient Entity
Duke Medical Center
Evaluate the Efficacy and Safety of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy No dispute reported 06/30/2026 850452397
Principal investigator 1 TG Therapeutics, Inc. $2,520.00 11/01/2021 Non-covered Recipient Entity
Duke Medical Center
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 No dispute reported 06/30/2026 850452247
Principal investigator 1 BeiGene, Ltd. $47,000.00 10/20/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843876635
Principal investigator 1 Merck Sharp & Dohme Corporation $81,071.48 10/05/2021 Non-covered Recipient Entity
DUKE CANCER CENTER
A Phase 1,2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies No dispute reported 06/30/2026 848740503
Principal investigator 1 BeiGene, Ltd. $1,826.09 09/15/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872663
Principal investigator 1 BeiGene, Ltd. $20,106.00 09/13/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874977
Principal investigator 1 BeiGene, Ltd. $28,958.00 09/13/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874979
Principal investigator 1 TG Therapeutics, Inc. $1,890.00 09/12/2021 Non-covered Recipient Entity
Duke Medical Center
(GENUINE) Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 850452267
Principal investigator 1 BeiGene, Ltd. $59.85 08/18/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872651
Principal investigator 1 BeiGene, Ltd. $2,830.00 08/18/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872653
Principal investigator 1 BeiGene, Ltd. $3,208.00 08/18/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872655
Principal investigator 1 BeiGene, Ltd. $3,209.00 08/18/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872657
Principal investigator 1 BeiGene, Ltd. $2,481.00 08/18/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872661
Principal investigator 1 BeiGene, Ltd. $47,000.00 07/29/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843878039
Principal investigator 1 BeiGene, Ltd. $13,787.10 07/26/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874975
Principal investigator 1 BeiGene, Ltd. $2,530.99 07/21/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872659
Principal investigator 1 Celgene Corporation $13,696.09 07/16/2021 Non-covered Recipient Entity
Duke University Health System
An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) No dispute reported 06/30/2026 807114779
Principal investigator 1 BeiGene, Ltd. $6,418.00 05/28/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872617
Principal investigator 1 BeiGene, Ltd. $119.70 05/28/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872627
Principal investigator 1 BeiGene, Ltd. $9,624.00 05/28/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872641
Principal investigator 1 BeiGene, Ltd. $8,490.00 05/28/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872643
Principal investigator 1 BeiGene, Ltd. $7,443.00 05/28/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872645
Principal investigator 1 Eli Lilly and Company $25,875.25 05/18/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 819456725
Principal investigator 1 BeiGene, Ltd. $5,341.28 05/14/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872625
Principal investigator 1 BeiGene, Ltd. $22,160.70 05/10/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874973
Principal investigator 1 BeiGene, Ltd. $47,000.00 05/05/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843876723
Principal investigator 1 BeiGene, Ltd. $173,106.39 04/30/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872629
Principal investigator 1 BeiGene, Ltd. $22,640.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872613
Principal investigator 1 BeiGene, Ltd. $312,273.17 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872615
Principal investigator 1 BeiGene, Ltd. $12,600.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872619
Principal investigator 1 BeiGene, Ltd. $166.25 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872621
Principal investigator 1 BeiGene, Ltd. $25,664.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872631
Principal investigator 1 BeiGene, Ltd. $19,848.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872633
Principal investigator 1 BeiGene, Ltd. $204.82 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872635
Principal investigator 1 BeiGene, Ltd. $266.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872637
Principal investigator 1 BeiGene, Ltd. $25,672.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872639
Principal investigator 1 BeiGene, Ltd. $780.00 04/16/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872649
Principal investigator 1 BeiGene, Ltd. $7,712.67 04/14/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872623
Principal investigator 1 BeiGene, Ltd. $2,650.69 04/14/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872647
Principal investigator 1 ABBVIE INC. $1,890.00 03/01/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma No dispute reported 06/30/2026 792426409
Principal investigator 1 BeiGene, Ltd. $18,800.00 02/10/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843876779
Principal investigator 1 BeiGene, Ltd. $18,289.00 02/08/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874969
Principal investigator 1 BeiGene, Ltd. $29,129.00 02/08/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874971
Principal investigator 1 BeiGene, Ltd. $5,201.63 02/04/2021 Non-covered Recipient Entity
Duke University
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 843872611
Principal investigator 1 Eli Lilly and Company $3,788.02 01/26/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 819456775
Principal investigator 1 BeiGene, Ltd. $10,654.20 01/25/2021 Non-covered Recipient Entity
Duke University
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 843874967
Principal investigator 1 Acerta Pharma LLC $20,347.94 01/21/2021 Non-covered Recipient Entity
DUKE UNIVERSITY
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 826465671